A 6-Month Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Once Daily Ciclesonide HFA Nasal Aerosol (80 and 160 mcg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older.

Trial Profile

A 6-Month Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Once Daily Ciclesonide HFA Nasal Aerosol (80 and 160 mcg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Mar 2013 Results from a post-hoc analysis, which included data from this trial, have been presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology according to a Sunovion Pharmaceuticals media release.
    • 08 Jun 2012 Actual patient number changed from 825 to 824 as reported by ClinicalTrials.gov. (Extension trial: NCT01067105)
    • 08 Jun 2012 Actual patient number changed from 825 to 824 as reported by ClinicalTrials.gov. (Extension trial: NCT01067105)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top